knowledge -WSS

knowledge

author：explore 2025-09-27 22:18:14 - browse：4651

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： In utero gene editing: an explainer

WSS

NIH director takes cautious approach to Biden drug pricing priority

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Alabama hospital puts IVF treatments on hold

Alabama hospital puts IVF treatments on hold

New documents shed light on MD Anderson Cancer Institute feud

Alabama hospital puts IVF treatments on hold

hotspot

knowledge

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

United colonoscopy coverage change 'may cost lives,' doctors say

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Hollywood unions extend contract negotiations for actors

STAT readers on older presidents, polypills, Medicare, and more

Bright Health sells Medicare Advantage business to Molina

How digital therapeutics firms are pivoting after Pear's bankruptcy

How to save PrEP access — and even expand it

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

focus

Test for long Covid? Researchers find new clue in blood samples

The Harvard botanist who searched for psychedelics in the Amazon

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

My yearlong odyssey to get my son’s ADHD medication covered

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

focus

focus

focus

focus